Bruno Émond
Education
M.Sc. and B.Sc., economics, Université de Sherbrooke
Summary of Experience
Mr. Émond specializes in biostatistics and economics within the field of health economics and outcomes research (HEOR). He has conducted a range of investigations into epidemiology, quality of life, patient-reported outcomes, cost of illness, resource utilization patterns, treatment patterns, cost-effectiveness, and treatment outcomes in the areas of oncology, hepatitis, chronic inflammatory diseases, epilepsy, diabetes mellitus, schizophrenia, cardiovascular diseases, infectious diseases, and hematology. Mr. Émond also has extensive experience performing retrospective database analyses, retrospective medical chart review studies, systematic literature reviews, cost models, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association (APA), International AIDS Society (IAS), American Society of Clinical Oncology (ASCO), and American Society of Hematology (ASH), and published articles in several peer-reviewed journals. Mr. Émond has served as a peer reviewer for The American Journal of Managed Care, CNS Drugs, and the Journal of Managed Care & Specialty Pharmacy, and is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer
Journal of medical economics, 2024
2024Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Lefebvre P, He A, Vanderpoel J
-
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Drugs - Real World Outcomes, 2024
2024Walsh JA, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu LH, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease P
-
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Current Oncology, 2023
2023Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P
-
Comparison of Clinical Outcomes in Patients with Schizophrenia Following Different Long-Acting Injectable Event-Driven Initiation Strategies
Schizophrenia, 2023
2023Correll C, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, Morrison L, Ghelerter I, Lefebvre P, Mavros P
-
Respiratory Syncytial Virus-Related Complications and Healthcare Costs among a Medicare-Insured Population in the United States
Open Forum Infectious Diseases, 2023
2023DeMartino JK, Lafeuille MH, Emond B, Rossi C, Wang J, Liu S, Lefebvre P, Krishnarajah G
-
Real-World Weight Changes in People with Hiv-1 at Risk of Weight Gain (Female, Black or Hispanic) Switching from Integrase Strand Transfer Inhibitors
Journal of Comparative Effectiveness Research, 2023
2023Donga P, Emond B, Shah A, Bookhart BK, Anderson D, Vermette-Laforme M, Rossi C, Lafeuille MH
-
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
PharmacoEconomics Open, 2023
2023Vanderpoel J, Emond B, Ghelerter I, Milbers K, Lafeuille MH, Lefebvre P, Ellis LA
-
Incidence of Cardiometabolic Outcomes among People Living with HIV-1 Initiated on Integrase Strand Transfer Inhibitor Versus Non-Integrase Strand Transfer Inhibitor Antiretroviral Therapies: A Retrospective Analysis of Insurance Claims in the United States
Journal of International AIDS Society, 2023
2023Rebeiro PF, Emond B, Rossi C, Bookhart BK, Shah A, Caron-Lapointe G, Lafeuille MH, Donga P
-
Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients with Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of Seer-Medicare Data
Clinical Genitourinary Cancer, 2023
2023Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Laliberté F, Emond B, Agarwal N
-
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Future Oncology, 2023
2023Jacobs R, Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Levy MY
-
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
Patient Preference and Adherence, 2023
2023Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R
-
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Current Medical Research and Opinion, 2023
2023Lu X, Emond B, Qureshi ZP, Wu LH, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Rogers KA
-
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
ClinicoEconomics and Outcomes Research, 2023
2023Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH
-
CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Lu X, Emond B, Qureshi Z, He J, Qian Y, Huang Q, Lefebvre P, Lafeuille MH, Jacobs R
-
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M
-
Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study
Journal of Managed Care & Specialty Pharmacy, 2022
2022Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
-
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States
Current Medical Research and Opinion, 2022
2022Liu J, Emond B, Maiese EM, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau JA, Thaker PH
-
Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
Infectious Diseases and Therapy, 2022
2022McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, Lafeuille MH, Donga P
-
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
Advances in Therapy, 2022
2022Wu JJ, Lafeuille MH, Emond B, Fakih I, Duh MS, Cappelleri JC, Yin N, Feeney C, Myers DE, DiBonaventura M
-
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases
Journal of Managed Care & Specialty Pharmacy, 2022
2022Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH
-
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
Journal of Medical Economics, 2022
2022Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L
-
Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab
Current Medical Research and Opinion, 2022
2022Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y
-
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Current Medical Research and Opinion, 2022
2022Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P
-
Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P
-
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
Current Medical Research and Opinion, 2021
2021Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
-
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study
Clinical Therapeutics, 2021
2021Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q
-
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
Journal of Health Economics and Outcomes Research, 2021
2021Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P
-
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
BMC Rheumatology, 2020
2020Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU
-
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Current Medical Research and Opinion, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H
-
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
Drugs - Real World Outcomes, 2020
2020Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC
-
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
Current Medical Research and Opinion, 2020
2020Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A
-
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans
Current Medical Research and Opinion, January 5, 2019
2019Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K
-
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records
Journal of Diabetes and its Complications, 2019
2019Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M
-
Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex
Epilepsia Open, 2019
2019Vergeer M, de Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Duh MS, Jansen F, Zonnenberg BA
-
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
Clinical Lymphoma, Myeloma & Leukemia, 2019
2019Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A
-
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
-
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors
Current Medical Research and Opinion, 2019
2019Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P
-
Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Romdhani H, Lefebvre P, Côté-Sergent A, Shohoudi A, Tandon N, Chow W, Dunn K
-
Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Lefebvre P, Lafeuille MH, Côté-Sergent A, Tandon N, Chow W, Dunn K
-
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Journal of Managed Care & Specialty Pharmacy. 2018 Oct;24(10):1040-1051
2018Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P
-
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Current Medical Research and Opinion. 2018 Jun;34(6):1125-1133
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Economic burden of treatment failure in chronic lymphocytic leukemia patients
Current Medical Research and Opinion. 2018 Jun;34(6):1135-1142
2018Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M
-
Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting
Endocrine Practice. 03 2018;24(3):273-287
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics
Current Medical Research and Opinion. Feb 28 2018:1-12.
2018Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K
-
Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
2018Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA
-
Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis
J Drugs Dermatol. Feb 1 2018;17(2):187-194
2018Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A
-
Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
Patient Preference and Adherence. 22 Mar 2017;11:619-629
2017Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P
-
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
Current Medical Research and Opinion. Oct 2017;33(10):1763-1772
2017Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
2017Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K
-
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
BMC Endocrine Disorders. Jun 08 2017;17(1):32
2017Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS
-
Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):225-235
2017Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA
-
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
2016Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.
-
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Prac
Clinical Lymphoma Myeloma and Leukemia, 2016 08. e-pub ahead of print 2016/10/01
2016Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.
-
April 11, 2024
-
December 1, 2023
-
October 23, 2023
-
July 25, 2023
-
June 27, 2023
-
June 8, 2023
-
December 7, 2022
-
March 29, 2022
-
June 4, 2021